Navigation Links
Tumor cells seek temporary shelter from cancer drugs
Date:4/1/2010

Results reported in the April 2nd issue of the journal Cell, a Cell Press publication, reveal a new source for the drug resistance that crops up all too often and quickly in the tumors of cancer patients undergoing therapy. First the bad news: all cancer cells might have the capacity to enter a drug-tolerant state. But there's some potentially very good news too: in some cases there may be a way to reverse or block cancer's drug resistance.

"The problem with cancer drug therapy is that even the ones that work well generally only work for a limited time because drug resistance develops," said Jeff Settleman of Harvard's Massachusetts General Hospital Cancer Center.

Scientists have thought that resistance primarily stems from genetic causes mutations in some tumor cells that may have pre-existed drug treatment. The theory holds that those drug-resistant mutants rise in prevalence with treatment as a classic example of survival of the fittest. "We're suggesting here that, while that may occur, there may be other non-genetic mechanisms [for drug resistance] that serve as a way to protect the tumor as a whole in a somewhat purposeful way," Settleman added.

While examining the acute response of human tumor cells in culture to various anti-cancer agents, Settleman and his colleague Marie Classon consistently detected a small subpopulation of reversibly "drug-tolerant" cells. Those cells were more than 100 times less sensitive to cancer drugs. They also found that the cells' drug tolerant state was transiently acquired and relinquished at low frequency by individual cells within the culture population.

The researchers don't yet know exactly how the cells manage that kind of reversible drug resistance, but they did uncover a couple of key features: the cells engage a signaling pathway including the IGF-1 receptor (which is a tyrosine kinase receptor) and their genetic material was also packaged differently into its three-dimensional structure (known as chromatin). That altered chromatin state depends on a particular enzyme that chemically modifies the histone proteins that are often likened to spools for DNA.

The new results add to other recent work suggesting that drug resistance might not always have to arise through genetic mutation, Settleman said. For example, accumulating evidence suggests that a small population of "cancer stem cells" is intrinsically more difficult to treat.

A handful of other studies have also raised the possibility that epigenetic mechanisms like the one now described might be at play, the researchers note. This path to reversible drug resistance may explain an increasingly observed phenomenon in cancer therapy -- the so-called "re-treatment response" in which cancer patients who have grown resistant to a variety of anticancer drugs can be successfully re-treated with the same drug after a "drug holiday."

The new study also suggests a promising new kind of combination cancer therapy designed to avoid drug resistance or as secondary treatment for cancers that have already developed resistance to other drugs. Indeed, the researchers found that their drug-tolerant cells in culture could be killed by treating them with IGF-1 receptor blockers or chromatin-modifying agents. "It presents a therapeutic opportunity," Classon said.

In fact, the researchers say they've already launched a clinical trial in patients with lung cancer to test a combination therapy including a chromatin-modifying agent and the drug erlotinib, which is a tyrosine kinase inhibitor.

"Although the trial is not yet completed, the early clinical data indicate that the inclusion of a chromatin-modifying agent can dramatically improve clinical benefit in a subset of patients demonstrating acquired tyrosine kinase inhibitor resistance," the researchers wrote in conclusion. "When considering that acquired drug resistance may involve multiple distinct molecular mechanisms that arise independently within the same patient, thereby complicating strategies to overcome such resistance with a single rationally targeted agent, the potential ability to prevent the development of resistance by disrupting a drug-tolerant state is provocative. However, further studies will certainly be required to establish the in vivo significance of the cell culture findings, as well as to determine more precisely the molecular mechanisms underlying reversible drug tolerance."


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Researchers quantify benefits of minimally invasive removal of hard-to-reach tumors
2. Improved device provides more rapid, comprehensive analysis of circulating tumor cells
3. Protein in Breast Tumors May Predict Chemo Response
4. Tumors hide out from the immune system by mimicking lymph nodes
5. Chemo Plus Synthetic Drug Shrunk Pancreatic Tumors
6. Tumors Use a Protein to Hide From Immune System
7. Breast Cancers Return in Original Tumor Site a Bad Sign
8. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
9. Miles for Hope’s Moving Towards A Cure(SM) Brain Tumor Walk in Boston Raising Funds for Brain Tumor Vaccine and Massachusetts General Hospital
10. Overcoming tumor resistance to anti-cancer agent TRAIL
11. Solid-pseudopapillary neoplasm of the pancreas or pancreatic endocrine tumor?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Antonio, TX (PRWEB) , ... February 12, 2016 , ... ... love, as expressed in Blue SKies Buddha, the biography of Rama - Dr. Frederick ... fact a love story, the love of a Buddhist teacher for teaching and helping ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, ...
(Date:2/12/2016)... Middletown, PA (PRWEB) , ... February 12, 2016 , ... ... year’s event will be held in Anaheim, CA at the Anaheim Convention Center. Almost ... they can see new therapy products in action, learn more about their chosen field ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... firm announced that nominations have closed for the ISE Southeast Awards 2016. Finalists ... be announced at the ISE® Southeast Executive Forum and Awards Gala on March ...
(Date:2/12/2016)... ... 12, 2016 , ... Every winter, someone is killed, injured or loses a ... Burn Center, part of the Allegheny Health Network, has partnered with Etna Volunteer ... Heaters Need Space” campaign. , “Space Heaters Need Space” aims to bring ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  Apellis Pharmaceuticals, Inc., today ... million Series D preferred stock financing, co-led ... Capital Group and venBio Global Strategic Fund, ... IB Investment, and Epidarex Capital. The proceeds of ... advance clinical trials in the Company,s ongoing ...
(Date:2/12/2016)... February 12, 2016 ... titled Chronic Inflammation Global Clinical Trials Review, H2, ... the global clinical trials landscape along with top ... Region, Country (G7 & E7), Trial Status, Trial ... reviews top companies involved and enlists all trials ...
(Date:2/11/2016)... , Feb. 11, 2016 The primary ... and future adoption patterns on the usage of liquid ... the following: - Timeframe of liquid biopsy ... ctDNA, cfDNA and Evs—by organization type - Sample inflow ... types: blood, saliva, stool, serum, and so on. - ...
Breaking Medicine Technology: